DV
Dividend Vision

ADTX — Aditxt Inc.

Aditxt Inc. (ADTX)

Its deepest 1-year drawdown was 100.0%.

Aditxt Inc. is a biopharmaceutical company developing diagnostic and therapeutic products focused on immune profiling, immunotherapy, and disease detection through mitochondrial DNA analysis. The company does not currently distribute dividends. Aditxt appeals to investors seeking exposure to early-stage biotech development rather than current income.

ADTX key facts

Asset type
Stock
Asset class
Equity
Inception date
06/30/2020
Last close
$0.0023
Market cap
$2,993,929
Average volume
8092952.0
Payout ratio
0.0
Forward P/E
0.3513
EPS
$-1,380.80